| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Education, Pharmacy | 33 | 2023 | 102 | 10.450 |
Why?
|
| Pharmaceutical Services | 12 | 2023 | 47 | 3.110 |
Why?
|
| Schools, Pharmacy | 12 | 2023 | 36 | 2.470 |
Why?
|
| Pharmacy | 8 | 2021 | 26 | 1.990 |
Why?
|
| Pharmacists | 11 | 2019 | 125 | 1.980 |
Why?
|
| Faculty | 8 | 2019 | 56 | 1.580 |
Why?
|
| Students, Pharmacy | 8 | 2019 | 79 | 1.300 |
Why?
|
| Teaching | 7 | 2011 | 169 | 1.300 |
Why?
|
| Societies, Pharmaceutical | 6 | 2021 | 22 | 1.290 |
Why?
|
| Pharmacy Service, Hospital | 6 | 2021 | 52 | 1.180 |
Why?
|
| Periodicals as Topic | 6 | 2014 | 158 | 1.160 |
Why?
|
| Leadership | 3 | 2019 | 136 | 1.080 |
Why?
|
| Education, Pharmacy, Graduate | 2 | 2023 | 18 | 0.900 |
Why?
|
| Humans | 128 | 2023 | 68618 | 0.830 |
Why?
|
| Medical Assistance | 4 | 2002 | 9 | 0.770 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 127 | 0.760 |
Why?
|
| Surgical Wound Infection | 12 | 2002 | 168 | 0.710 |
Why?
|
| Delivery of Health Care | 5 | 2023 | 445 | 0.690 |
Why?
|
| Immunosuppressive Agents | 5 | 2005 | 514 | 0.690 |
Why?
|
| Patient Care Team | 3 | 2013 | 311 | 0.690 |
Why?
|
| Anti-Bacterial Agents | 20 | 2002 | 1026 | 0.670 |
Why?
|
| Bacterial Infections | 8 | 1995 | 163 | 0.640 |
Why?
|
| Schools | 1 | 2019 | 156 | 0.610 |
Why?
|
| Kidney Transplantation | 6 | 2005 | 839 | 0.600 |
Why?
|
| United States | 17 | 2023 | 7367 | 0.590 |
Why?
|
| Congresses as Topic | 1 | 2017 | 85 | 0.580 |
Why?
|
| Personnel Selection | 2 | 2019 | 37 | 0.540 |
Why?
|
| Abdomen | 7 | 2002 | 80 | 0.510 |
Why?
|
| Tacrolimus | 3 | 2005 | 127 | 0.470 |
Why?
|
| Premedication | 10 | 1989 | 49 | 0.470 |
Why?
|
| Career Choice | 3 | 2013 | 98 | 0.460 |
Why?
|
| Editorial Policies | 2 | 2013 | 32 | 0.450 |
Why?
|
| Antibodies, Monoclonal | 4 | 2005 | 511 | 0.450 |
Why?
|
| Manuscripts, Medical as Topic | 1 | 2013 | 2 | 0.450 |
Why?
|
| Education, Distance | 2 | 2010 | 34 | 0.440 |
Why?
|
| Drug Industry | 4 | 2002 | 54 | 0.440 |
Why?
|
| Educational Technology | 2 | 2010 | 22 | 0.440 |
Why?
|
| Internship, Nonmedical | 1 | 2012 | 19 | 0.420 |
Why?
|
| Education, Graduate | 1 | 2012 | 30 | 0.420 |
Why?
|
| Cephalosporins | 7 | 1999 | 59 | 0.410 |
Why?
|
| Drug Prescriptions | 4 | 2002 | 135 | 0.410 |
Why?
|
| Immunoglobulin E | 4 | 1998 | 91 | 0.410 |
Why?
|
| Wounds and Injuries | 5 | 2006 | 334 | 0.400 |
Why?
|
| Sepsis | 5 | 1998 | 233 | 0.380 |
Why?
|
| Medicare | 2 | 2005 | 319 | 0.370 |
Why?
|
| Prescription Drugs | 1 | 2011 | 71 | 0.360 |
Why?
|
| Faculty, Pharmacy | 2 | 2020 | 13 | 0.360 |
Why?
|
| Education, Medical, Continuing | 1 | 2011 | 136 | 0.360 |
Why?
|
| Professional Competence | 3 | 2013 | 100 | 0.360 |
Why?
|
| Benchmarking | 1 | 2010 | 91 | 0.350 |
Why?
|
| Learning | 2 | 2010 | 186 | 0.340 |
Why?
|
| Curriculum | 6 | 2020 | 575 | 0.330 |
Why?
|
| Societies | 1 | 2009 | 15 | 0.330 |
Why?
|
| Drug Therapy, Combination | 5 | 1995 | 649 | 0.320 |
Why?
|
| Postoperative Complications | 7 | 2003 | 1615 | 0.320 |
Why?
|
| Publishing | 1 | 2009 | 89 | 0.300 |
Why?
|
| History, 21st Century | 3 | 2016 | 127 | 0.300 |
Why?
|
| Quality Improvement | 2 | 2013 | 413 | 0.300 |
Why?
|
| Cefoxitin | 5 | 1989 | 20 | 0.290 |
Why?
|
| History, 20th Century | 3 | 2016 | 248 | 0.290 |
Why?
|
| Surgical Procedures, Operative | 7 | 1996 | 124 | 0.290 |
Why?
|
| Schools, Medical | 1 | 2008 | 157 | 0.290 |
Why?
|
| Science | 1 | 2007 | 15 | 0.290 |
Why?
|
| Cyclosporine | 2 | 2005 | 121 | 0.280 |
Why?
|
| Gram-Negative Bacteria | 3 | 1997 | 55 | 0.260 |
Why?
|
| Prescription Fees | 1 | 2005 | 5 | 0.260 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2005 | 12 | 0.260 |
Why?
|
| Shock, Hemorrhagic | 3 | 1996 | 33 | 0.250 |
Why?
|
| Colon | 4 | 1999 | 168 | 0.250 |
Why?
|
| Amphotericin B | 2 | 2003 | 26 | 0.250 |
Why?
|
| Tuberculosis | 1 | 2005 | 77 | 0.240 |
Why?
|
| Candidiasis | 2 | 2003 | 39 | 0.240 |
Why?
|
| Educational Measurement | 1 | 2006 | 254 | 0.240 |
Why?
|
| Urinary Tract Infections | 3 | 2003 | 71 | 0.240 |
Why?
|
| Vancomycin | 4 | 1996 | 60 | 0.240 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2005 | 626 | 0.240 |
Why?
|
| Candida | 1 | 2003 | 15 | 0.230 |
Why?
|
| Antifungal Agents | 2 | 2003 | 108 | 0.230 |
Why?
|
| Aminoglycosides | 7 | 2002 | 54 | 0.230 |
Why?
|
| Antacids | 1 | 2003 | 26 | 0.230 |
Why?
|
| Medically Uninsured | 2 | 2002 | 99 | 0.220 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 481 | 0.210 |
Why?
|
| Rectum | 4 | 1999 | 62 | 0.210 |
Why?
|
| Interprofessional Relations | 2 | 2016 | 188 | 0.210 |
Why?
|
| Maine | 1 | 2022 | 3 | 0.210 |
Why?
|
| Guidelines as Topic | 3 | 2013 | 123 | 0.200 |
Why?
|
| Methotrexate | 1 | 2002 | 91 | 0.200 |
Why?
|
| Antipyrine | 4 | 1995 | 6 | 0.200 |
Why?
|
| Adult | 31 | 2005 | 21403 | 0.200 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2002 | 59 | 0.200 |
Why?
|
| Strategic Planning | 1 | 2021 | 1 | 0.190 |
Why?
|
| Faculty, Medical | 1 | 2022 | 110 | 0.190 |
Why?
|
| Abdominal Abscess | 4 | 2003 | 8 | 0.190 |
Why?
|
| Diffusion of Innovation | 2 | 2013 | 102 | 0.190 |
Why?
|
| Cefmetazole | 3 | 1989 | 3 | 0.190 |
Why?
|
| Peer Review, Research | 2 | 2013 | 21 | 0.190 |
Why?
|
| Medical Indigency | 1 | 2000 | 7 | 0.180 |
Why?
|
| Peritonitis | 4 | 2003 | 46 | 0.180 |
Why?
|
| Patient Care | 1 | 2000 | 61 | 0.180 |
Why?
|
| Pharmacies | 1 | 2019 | 18 | 0.170 |
Why?
|
| Antibiotic Prophylaxis | 1 | 1999 | 62 | 0.170 |
Why?
|
| Cefazolin | 5 | 1990 | 19 | 0.170 |
Why?
|
| Clinical Competence | 3 | 2020 | 657 | 0.160 |
Why?
|
| Mentors | 1 | 2019 | 81 | 0.160 |
Why?
|
| Internet | 3 | 2009 | 390 | 0.160 |
Why?
|
| Organ Transplantation | 1 | 2000 | 110 | 0.160 |
Why?
|
| Male | 38 | 2005 | 37321 | 0.160 |
Why?
|
| Drug Monitoring | 2 | 1998 | 107 | 0.160 |
Why?
|
| Electrophoresis, Capillary | 1 | 1998 | 15 | 0.160 |
Why?
|
| Hospitals | 1 | 2021 | 265 | 0.160 |
Why?
|
| Attitude of Health Personnel | 2 | 2013 | 442 | 0.160 |
Why?
|
| Lipoproteins, HDL | 2 | 1996 | 113 | 0.160 |
Why?
|
| Female | 37 | 2005 | 38074 | 0.160 |
Why?
|
| Annual Reports as Topic | 2 | 2018 | 12 | 0.160 |
Why?
|
| Professional-Patient Relations | 2 | 2013 | 71 | 0.160 |
Why?
|
| Leukocyte Count | 1 | 1998 | 94 | 0.150 |
Why?
|
| Polyethylene Glycols | 5 | 1987 | 149 | 0.150 |
Why?
|
| Eosinophils | 1 | 1998 | 60 | 0.150 |
Why?
|
| Health Personnel | 1 | 2020 | 286 | 0.150 |
Why?
|
| Professional Role | 3 | 2020 | 80 | 0.150 |
Why?
|
| Middle Aged | 24 | 2005 | 21147 | 0.150 |
Why?
|
| Biomedical Research | 2 | 2013 | 310 | 0.150 |
Why?
|
| Leishmaniasis | 1 | 1997 | 4 | 0.150 |
Why?
|
| Motivation | 2 | 2013 | 561 | 0.140 |
Why?
|
| Pharmacy and Therapeutics Committee | 3 | 2020 | 7 | 0.140 |
Why?
|
| Mycobacterium Infections | 1 | 1997 | 13 | 0.140 |
Why?
|
| Program Development | 2 | 2013 | 240 | 0.140 |
Why?
|
| Anti-Infective Agents | 3 | 2003 | 166 | 0.140 |
Why?
|
| Time Factors | 8 | 2013 | 4655 | 0.140 |
Why?
|
| Blood Proteins | 2 | 1993 | 94 | 0.140 |
Why?
|
| Cefuroxime | 2 | 1993 | 3 | 0.140 |
Why?
|
| Kinetics | 9 | 1993 | 1047 | 0.130 |
Why?
|
| Bacteria, Anaerobic | 3 | 1994 | 15 | 0.130 |
Why?
|
| Multiple Trauma | 1 | 1996 | 50 | 0.130 |
Why?
|
| Drug Therapy | 3 | 2013 | 71 | 0.130 |
Why?
|
| Interleukin-4 | 1 | 1995 | 69 | 0.130 |
Why?
|
| Resuscitation | 1 | 1996 | 77 | 0.130 |
Why?
|
| Interleukin-10 | 1 | 1996 | 144 | 0.130 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 1995 | 62 | 0.130 |
Why?
|
| Therapeutic Irrigation | 5 | 1987 | 63 | 0.120 |
Why?
|
| Bacteremia | 2 | 1996 | 155 | 0.120 |
Why?
|
| Hypertension | 2 | 2002 | 1535 | 0.120 |
Why?
|
| Forecasting | 2 | 2013 | 277 | 0.110 |
Why?
|
| Haptens | 1 | 1993 | 11 | 0.110 |
Why?
|
| Computers | 1 | 2013 | 63 | 0.110 |
Why?
|
| Cefonicid | 1 | 1993 | 2 | 0.110 |
Why?
|
| Drug Interactions | 5 | 2003 | 289 | 0.110 |
Why?
|
| Penicillins | 1 | 1993 | 32 | 0.110 |
Why?
|
| Ethics Committees, Research | 1 | 2013 | 22 | 0.110 |
Why?
|
| Interdisciplinary Communication | 1 | 2013 | 93 | 0.110 |
Why?
|
| Cytokines | 1 | 1997 | 866 | 0.100 |
Why?
|
| Indocyanine Green | 1 | 1992 | 4 | 0.100 |
Why?
|
| Shock, Traumatic | 1 | 1992 | 4 | 0.100 |
Why?
|
| Workload | 1 | 2013 | 103 | 0.100 |
Why?
|
| Lorazepam | 1 | 1992 | 54 | 0.100 |
Why?
|
| Social Responsibility | 1 | 2012 | 39 | 0.100 |
Why?
|
| Public Opinion | 1 | 2012 | 32 | 0.100 |
Why?
|
| Disease Models, Animal | 3 | 1997 | 2550 | 0.100 |
Why?
|
| Shock, Septic | 1 | 1992 | 101 | 0.100 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 235 | 0.100 |
Why?
|
| Electrolytes | 4 | 1987 | 47 | 0.100 |
Why?
|
| Georgia | 3 | 2002 | 161 | 0.100 |
Why?
|
| Intestines | 3 | 1990 | 114 | 0.100 |
Why?
|
| Intestinal Absorption | 4 | 1989 | 41 | 0.100 |
Why?
|
| Job Description | 1 | 2011 | 23 | 0.100 |
Why?
|
| Antibodies | 1 | 1992 | 241 | 0.100 |
Why?
|
| Liver | 3 | 1995 | 1118 | 0.100 |
Why?
|
| Anniversaries and Special Events | 1 | 2011 | 12 | 0.100 |
Why?
|
| Program Evaluation | 1 | 2013 | 502 | 0.090 |
Why?
|
| Organizational Culture | 1 | 2011 | 59 | 0.090 |
Why?
|
| Prospective Studies | 9 | 2019 | 3705 | 0.090 |
Why?
|
| Patient Compliance | 3 | 2005 | 402 | 0.090 |
Why?
|
| Animals | 16 | 2005 | 20881 | 0.090 |
Why?
|
| Guideline Adherence | 1 | 2013 | 287 | 0.090 |
Why?
|
| Professional Practice | 1 | 2010 | 47 | 0.090 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1990 | 4 | 0.090 |
Why?
|
| Acute Kidney Injury | 2 | 1994 | 232 | 0.090 |
Why?
|
| Communication Barriers | 1 | 2010 | 48 | 0.090 |
Why?
|
| Mezlocillin | 1 | 1989 | 1 | 0.090 |
Why?
|
| Biomarkers | 1 | 1995 | 1593 | 0.090 |
Why?
|
| Problem Solving | 1 | 2009 | 36 | 0.090 |
Why?
|
| Prazosin | 1 | 1989 | 10 | 0.090 |
Why?
|
| Antigens, Neoplasm | 1 | 1990 | 132 | 0.090 |
Why?
|
| Models, Educational | 1 | 2009 | 67 | 0.090 |
Why?
|
| Aztreonam | 1 | 1989 | 6 | 0.080 |
Why?
|
| Injections, Intravenous | 4 | 2003 | 215 | 0.080 |
Why?
|
| Comprehension | 1 | 2009 | 71 | 0.080 |
Why?
|
| Models, Biological | 5 | 1996 | 981 | 0.080 |
Why?
|
| Bacteria | 4 | 1989 | 193 | 0.080 |
Why?
|
| Computer-Assisted Instruction | 1 | 2009 | 74 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2005 | 151 | 0.080 |
Why?
|
| HIV Infections | 1 | 1997 | 791 | 0.080 |
Why?
|
| Research Design | 1 | 2013 | 729 | 0.080 |
Why?
|
| Random Allocation | 6 | 1997 | 442 | 0.080 |
Why?
|
| Manuscripts as Topic | 1 | 2008 | 3 | 0.080 |
Why?
|
| Swine | 4 | 1997 | 672 | 0.080 |
Why?
|
| Glycosuria | 1 | 1988 | 2 | 0.080 |
Why?
|
| Cephamycins | 1 | 1988 | 10 | 0.080 |
Why?
|
| Evidence-Based Practice | 1 | 2009 | 146 | 0.080 |
Why?
|
| Antibody Specificity | 3 | 1994 | 98 | 0.080 |
Why?
|
| Half-Life | 6 | 1996 | 96 | 0.080 |
Why?
|
| Drug Costs | 2 | 2002 | 87 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 767 | 0.070 |
Why?
|
| Aging | 1 | 1993 | 911 | 0.070 |
Why?
|
| Digestive System Surgical Procedures | 5 | 1986 | 30 | 0.070 |
Why?
|
| Gentamicins | 3 | 1995 | 68 | 0.070 |
Why?
|
| Anthrax | 1 | 2006 | 6 | 0.070 |
Why?
|
| Rabies | 1 | 2006 | 5 | 0.070 |
Why?
|
| Tetanus | 1 | 2006 | 11 | 0.070 |
Why?
|
| Vaccines | 1 | 2006 | 21 | 0.070 |
Why?
|
| Biomarkers, Tumor | 1 | 1990 | 508 | 0.070 |
Why?
|
| Cefamandole | 2 | 1985 | 5 | 0.070 |
Why?
|
| Cimetidine | 2 | 1985 | 25 | 0.070 |
Why?
|
| Abscess | 1 | 1986 | 37 | 0.070 |
Why?
|
| Etanercept | 1 | 2005 | 12 | 0.070 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 32 | 0.070 |
Why?
|
| Infliximab | 1 | 2005 | 16 | 0.070 |
Why?
|
| Adalimumab | 1 | 2005 | 16 | 0.070 |
Why?
|
| Postal Service | 1 | 2005 | 19 | 0.060 |
Why?
|
| Splenectomy | 4 | 2006 | 40 | 0.060 |
Why?
|
| Community Pharmacy Services | 1 | 2005 | 11 | 0.060 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2005 | 35 | 0.060 |
Why?
|
| Abdominal Muscles | 1 | 1985 | 25 | 0.060 |
Why?
|
| Universities | 2 | 2019 | 191 | 0.060 |
Why?
|
| Cathartics | 1 | 1985 | 7 | 0.060 |
Why?
|
| Antirheumatic Agents | 1 | 2005 | 59 | 0.060 |
Why?
|
| Erythromycin | 1 | 1985 | 13 | 0.060 |
Why?
|
| Adolescent | 12 | 2002 | 8912 | 0.060 |
Why?
|
| Mycoses | 1 | 2005 | 60 | 0.060 |
Why?
|
| Length of Stay | 4 | 1998 | 780 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2005 | 931 | 0.060 |
Why?
|
| Constipation | 1 | 1985 | 32 | 0.060 |
Why?
|
| Cost Savings | 1 | 2005 | 110 | 0.060 |
Why?
|
| Vaccination | 1 | 2006 | 189 | 0.060 |
Why?
|
| Digoxin | 4 | 1988 | 24 | 0.060 |
Why?
|
| Neomycin | 1 | 1985 | 56 | 0.060 |
Why?
|
| Microbial Sensitivity Tests | 2 | 1996 | 226 | 0.060 |
Why?
|
| Tissue Distribution | 4 | 1990 | 282 | 0.060 |
Why?
|
| Protein Binding | 3 | 1993 | 1027 | 0.060 |
Why?
|
| Muscles | 3 | 1990 | 158 | 0.060 |
Why?
|
| Infection Control | 1 | 1984 | 101 | 0.060 |
Why?
|
| Colonoscopy | 2 | 1985 | 156 | 0.060 |
Why?
|
| Cholecystectomy | 3 | 1993 | 79 | 0.060 |
Why?
|
| Infant, Newborn | 5 | 1996 | 2455 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2005 | 234 | 0.060 |
Why?
|
| Antihypertensive Agents | 2 | 2000 | 498 | 0.050 |
Why?
|
| Biological Assay | 1 | 1983 | 88 | 0.050 |
Why?
|
| Intraoperative Period | 3 | 1989 | 62 | 0.050 |
Why?
|
| Directories as Topic | 1 | 2002 | 4 | 0.050 |
Why?
|
| MEDLINE | 1 | 2002 | 9 | 0.050 |
Why?
|
| Crohn Disease | 1 | 2002 | 38 | 0.050 |
Why?
|
| Digestive System Diseases | 1 | 2002 | 16 | 0.050 |
Why?
|
| Colitis, Ulcerative | 1 | 2002 | 53 | 0.050 |
Why?
|
| Lipopolysaccharides | 2 | 1994 | 455 | 0.050 |
Why?
|
| Drug Utilization | 1 | 1982 | 119 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2002 | 65 | 0.050 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 1996 | 123 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2002 | 239 | 0.050 |
Why?
|
| Aged | 12 | 2003 | 14862 | 0.050 |
Why?
|
| Fees, Pharmaceutical | 1 | 2000 | 7 | 0.050 |
Why?
|
| Licensure | 1 | 2020 | 18 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 1996 | 137 | 0.050 |
Why?
|
| Spironolactone | 1 | 1980 | 13 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2001 | 193 | 0.050 |
Why?
|
| Radioimmunoassay | 1 | 1980 | 164 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2002 | 291 | 0.050 |
Why?
|
| Policy Making | 1 | 2020 | 51 | 0.050 |
Why?
|
| Health Services Research | 1 | 2002 | 209 | 0.050 |
Why?
|
| Resilience, Psychological | 1 | 2020 | 43 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2020 | 73 | 0.040 |
Why?
|
| Gastrointestinal Agents | 1 | 2000 | 51 | 0.040 |
Why?
|
| Electrophoresis | 3 | 1995 | 69 | 0.040 |
Why?
|
| Hypolipidemic Agents | 1 | 2000 | 82 | 0.040 |
Why?
|
| Problem-Based Learning | 1 | 2020 | 72 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 4 | 1986 | 450 | 0.040 |
Why?
|
| Pain, Postoperative | 2 | 1993 | 214 | 0.040 |
Why?
|
| Retrospective Studies | 6 | 1998 | 7277 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2003 | 4848 | 0.040 |
Why?
|
| Drug Administration Schedule | 4 | 2002 | 567 | 0.040 |
Why?
|
| Theophylline | 3 | 1989 | 22 | 0.040 |
Why?
|
| Apolipoprotein A-I | 2 | 1996 | 29 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2002 | 322 | 0.040 |
Why?
|
| Efficiency | 1 | 1979 | 49 | 0.040 |
Why?
|
| Clinical Trials as Topic | 3 | 1994 | 848 | 0.040 |
Why?
|
| Colostomy | 2 | 1989 | 15 | 0.040 |
Why?
|
| Analysis of Variance | 3 | 1996 | 1040 | 0.040 |
Why?
|
| Solutions | 4 | 1987 | 115 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2000 | 504 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1992 | 381 | 0.040 |
Why?
|
| Serum Albumin | 2 | 1993 | 104 | 0.040 |
Why?
|
| Task Performance and Analysis | 1 | 1979 | 150 | 0.040 |
Why?
|
| Cesarean Section | 3 | 1984 | 101 | 0.040 |
Why?
|
| Citric Acid | 1 | 1997 | 16 | 0.040 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1997 | 17 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2000 | 622 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2000 | 362 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 1980 | 301 | 0.040 |
Why?
|
| Triglycerides | 2 | 1995 | 184 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2000 | 458 | 0.040 |
Why?
|
| Th2 Cells | 1 | 1997 | 48 | 0.040 |
Why?
|
| Pneumonia | 1 | 1998 | 110 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2002 | 7029 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2002 | 581 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 1997 | 80 | 0.040 |
Why?
|
| Interleukins | 1 | 1997 | 79 | 0.040 |
Why?
|
| Heparin | 1 | 1997 | 205 | 0.030 |
Why?
|
| Th1 Cells | 1 | 1997 | 101 | 0.030 |
Why?
|
| Carbapenems | 1 | 1996 | 7 | 0.030 |
Why?
|
| Risk Factors | 5 | 2003 | 5731 | 0.030 |
Why?
|
| Fluoroquinolones | 1 | 1996 | 49 | 0.030 |
Why?
|
| Spectrophotometry, Ultraviolet | 2 | 1993 | 79 | 0.030 |
Why?
|
| Administration, Oral | 3 | 1995 | 411 | 0.030 |
Why?
|
| Glucose | 1 | 1997 | 307 | 0.030 |
Why?
|
| Communication | 1 | 2018 | 329 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1997 | 185 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 1996 | 76 | 0.030 |
Why?
|
| Superinfection | 1 | 1995 | 1 | 0.030 |
Why?
|
| Ticarcillin | 1 | 1995 | 2 | 0.030 |
Why?
|
| Clavulanic Acids | 1 | 1995 | 3 | 0.030 |
Why?
|
| Weightlessness | 1 | 1995 | 25 | 0.030 |
Why?
|
| Clindamycin | 1 | 1995 | 25 | 0.030 |
Why?
|
| Glycerol | 1 | 1995 | 26 | 0.030 |
Why?
|
| Anticoagulants | 1 | 1997 | 356 | 0.030 |
Why?
|
| Hospitalization | 2 | 1998 | 978 | 0.030 |
Why?
|
| Multiple Organ Failure | 1 | 1995 | 36 | 0.030 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 1995 | 34 | 0.030 |
Why?
|
| Housing, Animal | 1 | 1994 | 16 | 0.030 |
Why?
|
| Body Water | 1 | 1994 | 35 | 0.030 |
Why?
|
| Acidosis | 1 | 1994 | 31 | 0.030 |
Why?
|
| Oxygen | 2 | 1994 | 386 | 0.030 |
Why?
|
| Appendicitis | 1 | 1994 | 55 | 0.030 |
Why?
|
| Blood Pressure | 3 | 1997 | 1451 | 0.030 |
Why?
|
| Tablets | 2 | 1992 | 19 | 0.030 |
Why?
|
| Morphine | 2 | 1993 | 76 | 0.030 |
Why?
|
| Ultrafiltration | 1 | 1993 | 35 | 0.030 |
Why?
|
| Infusions, Intravenous | 4 | 1996 | 334 | 0.030 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 1993 | 29 | 0.030 |
Why?
|
| Drug Hypersensitivity | 1 | 1993 | 35 | 0.030 |
Why?
|
| Child | 6 | 2002 | 6405 | 0.030 |
Why?
|
| Delayed-Action Preparations | 2 | 1992 | 120 | 0.030 |
Why?
|
| Research Personnel | 1 | 2013 | 83 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1994 | 1745 | 0.030 |
Why?
|
| Nausea | 1 | 1992 | 47 | 0.030 |
Why?
|
| Immunologic Techniques | 1 | 1992 | 30 | 0.030 |
Why?
|
| Buprenorphine | 1 | 1993 | 67 | 0.030 |
Why?
|
| Hypertriglyceridemia | 1 | 1992 | 21 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 1992 | 48 | 0.030 |
Why?
|
| Vomiting | 1 | 1992 | 56 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 1992 | 26 | 0.030 |
Why?
|
| Genital Diseases, Female | 2 | 1983 | 23 | 0.030 |
Why?
|
| Antibody Formation | 1 | 1992 | 93 | 0.030 |
Why?
|
| Pharmaceutical Preparations | 2 | 1995 | 101 | 0.030 |
Why?
|
| Communicable Diseases | 1 | 1992 | 50 | 0.030 |
Why?
|
| Escherichia coli | 1 | 1994 | 368 | 0.020 |
Why?
|
| Hysterectomy | 2 | 1982 | 64 | 0.020 |
Why?
|
| Wounds, Penetrating | 1 | 1991 | 45 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 1992 | 420 | 0.020 |
Why?
|
| Evidence-Based Medicine | 2 | 2006 | 438 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 1992 | 172 | 0.020 |
Why?
|
| Thoracic Surgery | 2 | 1983 | 72 | 0.020 |
Why?
|
| Abdominal Injuries | 1 | 1991 | 60 | 0.020 |
Why?
|
| Orthopedics | 2 | 1983 | 88 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 1990 | 119 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 1990 | 122 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 1990 | 160 | 0.020 |
Why?
|
| Bile | 1 | 1989 | 35 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 1989 | 35 | 0.020 |
Why?
|
| Osmosis | 1 | 1989 | 38 | 0.020 |
Why?
|
| Community-Acquired Infections | 2 | 2003 | 46 | 0.020 |
Why?
|
| Mice, Nude | 1 | 1990 | 294 | 0.020 |
Why?
|
| Growth Hormone | 1 | 1989 | 51 | 0.020 |
Why?
|
| Analgesia | 1 | 1990 | 58 | 0.020 |
Why?
|
| Clonidine | 1 | 1989 | 66 | 0.020 |
Why?
|
| Phenytoin | 2 | 1988 | 27 | 0.020 |
Why?
|
| Immunotherapy | 1 | 1990 | 215 | 0.020 |
Why?
|
| Cefotetan | 1 | 1988 | 3 | 0.020 |
Why?
|
| Pregnancy | 3 | 1985 | 2334 | 0.020 |
Why?
|
| Sodium Chloride | 2 | 1985 | 136 | 0.020 |
Why?
|
| Self Administration | 1 | 1990 | 419 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1988 | 54 | 0.020 |
Why?
|
| Terbutaline | 1 | 1987 | 23 | 0.020 |
Why?
|
| Patient Selection | 2 | 2002 | 592 | 0.020 |
Why?
|
| Infant | 2 | 2002 | 2891 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2002 | 3187 | 0.020 |
Why?
|
| Hemodynamics | 3 | 1997 | 705 | 0.020 |
Why?
|
| Narcotics | 1 | 1987 | 65 | 0.020 |
Why?
|
| Cross Infection | 2 | 1995 | 195 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 1988 | 219 | 0.020 |
Why?
|
| Drug Contamination | 1 | 1986 | 10 | 0.020 |
Why?
|
| Urology | 1 | 1986 | 31 | 0.020 |
Why?
|
| Absorption | 1 | 1986 | 49 | 0.020 |
Why?
|
| Tetanus Toxoid | 1 | 2006 | 11 | 0.020 |
Why?
|
| Rabies Vaccines | 1 | 2006 | 4 | 0.020 |
Why?
|
| Anthrax Vaccines | 1 | 2006 | 5 | 0.020 |
Why?
|
| Gram-Positive Bacteria | 1 | 1986 | 23 | 0.020 |
Why?
|
| Obstetrics | 1 | 1986 | 44 | 0.020 |
Why?
|
| Gynecology | 1 | 1986 | 46 | 0.020 |
Why?
|
| Bioterrorism | 1 | 2006 | 12 | 0.020 |
Why?
|
| Neurosurgery | 1 | 1986 | 42 | 0.020 |
Why?
|
| Cell Line | 1 | 1990 | 1752 | 0.020 |
Why?
|
| Digestive System | 1 | 1986 | 35 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 1986 | 107 | 0.020 |
Why?
|
| Emollients | 1 | 1985 | 2 | 0.020 |
Why?
|
| Lubrication | 1 | 1985 | 8 | 0.020 |
Why?
|
| Medication Systems, Hospital | 1 | 1985 | 19 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 3 | 1995 | 2083 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 1985 | 57 | 0.020 |
Why?
|
| Dietary Fiber | 1 | 1985 | 37 | 0.020 |
Why?
|
| Hysterectomy, Vaginal | 1 | 1984 | 4 | 0.020 |
Why?
|
| Hip Fractures | 1 | 1985 | 26 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 1985 | 134 | 0.020 |
Why?
|
| Femoral Fractures | 1 | 1985 | 45 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 1984 | 47 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 1984 | 12 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 1986 | 156 | 0.020 |
Why?
|
| Reward | 1 | 2006 | 201 | 0.010 |
Why?
|
| Fat Emulsions, Intravenous | 2 | 1995 | 18 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 1985 | 219 | 0.010 |
Why?
|
| Gastroenterology | 1 | 1985 | 98 | 0.010 |
Why?
|
| Diet | 1 | 1987 | 514 | 0.010 |
Why?
|
| Decision Making | 1 | 1987 | 410 | 0.010 |
Why?
|
| Delivery, Obstetric | 1 | 1983 | 58 | 0.010 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 1983 | 36 | 0.010 |
Why?
|
| Formularies as Topic | 1 | 1982 | 5 | 0.010 |
Why?
|
| Societies, Medical | 1 | 1985 | 403 | 0.010 |
Why?
|
| Rats | 3 | 1995 | 5300 | 0.010 |
Why?
|
| Drug Stability | 2 | 1995 | 71 | 0.010 |
Why?
|
| Infusion Pumps | 2 | 1993 | 39 | 0.010 |
Why?
|
| Age Factors | 1 | 2006 | 1864 | 0.010 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 1981 | 9 | 0.010 |
Why?
|
| Obstetric Labor Complications | 1 | 1981 | 20 | 0.010 |
Why?
|
| Hip Prosthesis | 1 | 1982 | 85 | 0.010 |
Why?
|
| Neoplasms | 1 | 1992 | 1667 | 0.010 |
Why?
|
| Appendectomy | 1 | 1981 | 47 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 1981 | 168 | 0.010 |
Why?
|
| Incidence | 2 | 1995 | 1603 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2002 | 880 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1982 | 307 | 0.010 |
Why?
|
| Work | 1 | 1979 | 12 | 0.010 |
Why?
|
| Dogs | 2 | 1992 | 490 | 0.010 |
Why?
|
| Mice | 1 | 1990 | 8474 | 0.010 |
Why?
|
| Blood Coagulation Factors | 1 | 1997 | 44 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 219 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 1982 | 694 | 0.010 |
Why?
|
| Temperature | 2 | 1987 | 341 | 0.010 |
Why?
|
| Tail | 1 | 1995 | 8 | 0.010 |
Why?
|
| Capillary Action | 1 | 1995 | 3 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1995 | 144 | 0.010 |
Why?
|
| Parenteral Nutrition | 1 | 1995 | 39 | 0.010 |
Why?
|
| Organ Size | 1 | 1995 | 242 | 0.010 |
Why?
|
| Spleen | 1 | 1995 | 301 | 0.010 |
Why?
|
| Alkalosis | 1 | 1994 | 5 | 0.010 |
Why?
|
| Phosphatidylcholines | 1 | 1994 | 38 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1994 | 196 | 0.010 |
Why?
|
| Respiratory Tract Infections | 1 | 1995 | 91 | 0.010 |
Why?
|
| Micelles | 1 | 1993 | 43 | 0.010 |
Why?
|
| Chromatography | 1 | 1993 | 47 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 1994 | 112 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 1994 | 78 | 0.010 |
Why?
|
| Electrochemistry | 1 | 1993 | 70 | 0.010 |
Why?
|
| Placebos | 1 | 1994 | 195 | 0.010 |
Why?
|
| Rabbits | 1 | 1994 | 509 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1994 | 304 | 0.010 |
Why?
|
| Population Surveillance | 1 | 1995 | 285 | 0.010 |
Why?
|
| Acetaminophen | 1 | 1993 | 111 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1993 | 249 | 0.010 |
Why?
|
| Capsules | 1 | 1992 | 18 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1994 | 567 | 0.010 |
Why?
|
| Carboxyhemoglobin | 1 | 1992 | 2 | 0.010 |
Why?
|
| Methemoglobin | 1 | 1992 | 7 | 0.010 |
Why?
|
| Administration, Cutaneous | 1 | 1992 | 56 | 0.010 |
Why?
|
| Biological Availability | 1 | 1992 | 79 | 0.010 |
Why?
|
| Microspheres | 1 | 1992 | 59 | 0.010 |
Why?
|
| Blood Gas Analysis | 1 | 1992 | 41 | 0.010 |
Why?
|
| Pain Measurement | 1 | 1993 | 328 | 0.010 |
Why?
|
| Body Weight | 1 | 1994 | 554 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1991 | 47 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 1991 | 57 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 1992 | 218 | 0.010 |
Why?
|
| beta-Lactams | 1 | 1991 | 29 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 1996 | 772 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1992 | 765 | 0.010 |
Why?
|
| Cholesterol | 1 | 1992 | 331 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1992 | 737 | 0.010 |
Why?
|
| Computer Simulation | 1 | 1994 | 706 | 0.010 |
Why?
|
| Brain | 1 | 1981 | 2176 | 0.010 |
Why?
|
| Injections | 1 | 1990 | 119 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1989 | 65 | 0.010 |
Why?
|
| Creatinine | 1 | 1989 | 243 | 0.000 |
Why?
|
| Hypnotics and Sedatives | 1 | 1989 | 96 | 0.000 |
Why?
|
| Drug Packaging | 1 | 1987 | 4 | 0.000 |
Why?
|
| Drug Storage | 1 | 1987 | 16 | 0.000 |
Why?
|
| Syringes | 1 | 1987 | 15 | 0.000 |
Why?
|
| Defecation | 1 | 1987 | 8 | 0.000 |
Why?
|
| Gastrointestinal Motility | 1 | 1987 | 52 | 0.000 |
Why?
|
| Intestinal Diseases | 1 | 1987 | 25 | 0.000 |
Why?
|
| Histamine H2 Antagonists | 1 | 1987 | 45 | 0.000 |
Why?
|
| Food | 1 | 1987 | 52 | 0.000 |
Why?
|
| Candida albicans | 1 | 1986 | 39 | 0.000 |
Why?
|
| Warfarin | 1 | 1987 | 93 | 0.000 |
Why?
|
| Gastric Lavage | 1 | 1985 | 2 | 0.000 |
Why?
|
| Isotonic Solutions | 1 | 1985 | 25 | 0.000 |
Why?
|
| Enema | 1 | 1985 | 23 | 0.000 |
Why?
|
| Anesthesia | 1 | 1987 | 120 | 0.000 |
Why?
|
| Barium Sulfate | 1 | 1985 | 66 | 0.000 |
Why?
|
| Anesthesia, General | 1 | 1985 | 86 | 0.000 |
Why?
|
| Risk | 1 | 1982 | 563 | 0.000 |
Why?
|
| Smoking | 1 | 1987 | 1452 | 0.000 |
Why?
|
| Kidney | 1 | 1982 | 945 | 0.000 |
Why?
|